Citations

Clear

4847 citation(s) found for "Yu, Eric".

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Gelman, Rebecca , Anders, Carey K. , Melisko, Michelle , Parsons, Heather A. , Cropp, Anne B., Silvestri, Kelly M., Cotter, Christine M., Componeschi, Kathryn P., Marte, Juan M., Connolly, Roisín M. , Poznak, Catherine Van , Blackwell, Kimberly , Puhalla, Shannon L. , Jankowitz, Rachel C. , Ibrahim, Nuhad K. , Moynihan, Timothy J. , O’Sullivan, Ciara C. , Nangia, Julie R. , Pohlmann, Paula R. , Burns, Robyn, Rimawi, Mothaffar F. , Krop, Ian E. , O'Sullivan, Ciara C, Rimawi, Mothaffar , Freedman, Rachel A. , Moy, Beverly , Smith, Karen L. , Niravath, Polly Ann , Tung, Nadine , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U. , Pohlmann, Paula

Mayo Clinic

Journal of Clinical Oncology | March 12, 2019 | Volume: 37 | Issue: 13 | Pages: 1081-1089

10.1200/jco.18.01511 | PMID 30860945 Get It

PURPOSE Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from additional study cohorts. PATIENTS AND METHODS Patients with measurable, progressive, HER2-positive brain metastases (92% after receiving CNS surgery and/or radiotherapy) received neratinib 240 mg orally once per day plus capecitabine 750 mg/m 2 twice per day for 14 days, then 7 days off. Lapatinib-naïve (cohort 3A) and lapatinib-treated (cohort 3B) patients were enrolled. If nine or more of 35 (cohort 3A) or three or more of 25 (cohort 3B) had CNS objective response rates (ORR), the drug combination would be deemed promising. The primary end point was composite CNS ORR in each cohort separately, requiring a reduction of 50% or more in the sum of target CNS lesion volumes without progression of nontarget lesions, new lesions, escalating steroids, progressive neurologic signs or symptoms, or non-CNS progression. RESULTS Forty-nine patients enrolled in cohorts 3A (n = 37) and 3B (n = 12; cohort closed for slow accrual). In cohort 3A, the composite CNS ORR = 49% (95% CI, 32% to 66%), and the CNS ORR in cohort 3B = 33% (95% CI, 10% to 65%). Median progression-free survival was 5.5 and 3.1 months in cohorts 3A and 3B, respectively; median survival was 13.3 and 15.1 months. Diarrhea was the most common grade 3 toxicity (29% in cohorts 3A and 3B). Neratinib plus capecitabine is active against refractory, HER2-positive breast cancer brain metastases, adding additional evidence that the efficacy of HER2-directed therapy in the brain is enhanced by chemotherapy. For optimal tolerance, efforts to minimize diarrhea are warranted.
Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study.
Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Meyer, Meghan E., Tamimi, Rulla M. , Borges, Virginia F. , Winer, Eric P. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 515-515

10.1200/jco.2015.33.15_suppl.515 Get It

Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
Egyed, Miklós , Szőke, Anita , Suvorov, Aleksandr , Mayer, Jiří , Jourdan, Éric , Schouten, Harry C. , Tosi, Patrizia , Dean, James , Cernohous, Paul, Nangalia, Jyoti , Harrison, Claire , Mesa, Ruben A. , Perkins, Andrew C. , Ganly, Peter S. , Farber, Charles Michael , Zachée, Pierre , Scheid, Christof , Kiladjian, Jean‐Jacques , Vannucchi, Alessandro M. , Mead, Adam J.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: LBA7006-LBA7006

10.1200/jco.2015.33.15_suppl.lba7006 Get It

Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database.
Renfro, Lindsay A. , Haller, Daniel G. , Twelves, Chris , Guthrie, Katherine A. , Gramont, Aimery de , Allegra, Carmen J. , Group, ACCENT Collaborative, Cheung, Winson Y. , Yothers, Greg , Gray, Richard , André, Thierry , Cutsem, Eric Van , Saltz, Leonard B. , Grothey, Axel , Labianca, Roberto , Alberts, Steven R. , Schmoll, Hans‐Joachim , Sargent, Daniel J. , Group, ACCENT Collaborative

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6580-6580

10.1200/jco.2015.33.15_suppl.6580 Get It

Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.
Pavel, Marianne, Lam, Du, Kunz, Tiffany, Brandt, Ulrike , Capdevila, Jaume , Tomassetti, Paola, Hobday, Timothy J. , Pommier, Rodney F. , Lombard‐Bohas, Catherine , Cutsem, Eric Van , Vries, Elisabeth G.E. de , Yao, James C.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4091-4091

10.1200/jco.2015.33.15_suppl.4091 Get It

Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.
Ahmad, Syed A. , Marsh, Robert , Collisson, Eric A. , Schwartz, Lawrence H., Martin, Robert C.G. , Conway, William, Truty, Mark J. , Kindler, Hedy L. , Lowy, Andrew M. , Philip, Philip Agop, Cardin, Dana B. , LoConte, Noelle K. , Cardin, Dana B , LoConte, Noelle , Katz, Matthew H. G. , Shi, Qian , Herman, Joseph M. , Bekaii‐Saab, Tanios , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4008-4008

10.1200/jco.2015.33.15_suppl.4008 Get It

Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.
Grothey, Axel, Humblet, Yves, Mineur, Laurent , Adenis, Antoine , Lenz, Heinz‐Josef , Goldberg, Richard M. , Wagner, Andrea, Falcone, Alfredo , Bouché, Olivier , Tabernero, Josep , Yoshino, Takayuki , Xu, Lei , Wagner, Andrea, Cutsem, Eric Van

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e14579-e14579

10.1200/jco.2015.33.15_suppl.e14579 Get It

Sporadic angiomyolipomas (AMLs) growth kinetics while on everolimus (SAGE).
Kadow, Brian T. , Shuch, Brian , Boorjian, Stephen A. , Rampersaud, Edward N. , McClean, Daniel, Milestone, Barton N., Zibelman, Matthew R. , Smaldone, Marc C., Viterbo, Rosalia, Joshi, Shreyas , Greenberg, Richard E. , Malizzia, Lois, McGowan, Thomas, Geynisman, Daniel M. , Matin, Surena F. , Plimack, Elizabeth R. , Kutikov, Alexander , Chen, David , McGowan, Thomas, Ross, Eric A. , Uzzo, Robert G.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 560-560

10.1200/jco.2019.37.7_suppl.560 Get It

560 Background: Level I evidence exists demonstrating the efficacy of the mTOR inhibitor everolimus (EVE) in decreasing tumor volume of syndromic angiomyolipomas (AMLs) among patients with Tuberous Sclerosis. No prospective data are available regarding the effect of mTOR inhibition on growth kinetics in patients with sporadic AMLs. Methods: We conducted a multi-institutional, prospective, phase 2 trial with an optimal two-stage Simon design in patients presenting with > 3cm sporadic AMLs who were candidates for surgical or percutaneous intervention. Response was defined as ≥25% volumetric reduction of the AML. Planned enrollment was 43 patients to test the null hypothesis at a 5% level of significance with 80% power. Baseline, 4- and 6-month volumetric analysis was performed by dynamic contrast-enhanced MRI (DCE-MRI). Patients received EVE 10mg for four 28-day cycles, at which point EVE was discontinued in those with < 25% volumetric reduction. Those with ≥ 25% volumetric reduction received two additional cycles of EVE. Dose reductions and interruptions were allowed to 5 mg QOD. Conservative stopping rules were established for toxicity, given the benign nature of AMLs. Results: The early stopping rules for both efficacy and toxicity were invoked. We enrolled 20 patients (median age = 68) from 5 centers with 21 sporadic AMLs. 11/20 (55%) patients completed 4 cycles of EVE, while 7/20 (35%) completed 6 cycles. Median days on treatment was 88 (2 cycles). 4/20 (20%) patients were withdrawn due to toxicity, while 8/20 (40%) withdrew due to personal preference. Dose reductions were required in 6/20 (30%) patients, and 5/20 (25%) patients had grade 3 toxicities which resolved upon discontinuation or dose reduction of EVE. At 4-month MRI, 10/16 (62.5%) patients had a ≥25% reduction in volume (mean = 54.1% decrease). At 6-month MRI, 8/12 (66.6%) patients had a ≥25% reduction in volume (mean = 51.5% decrease). Conclusions: EVE was effective in reducing tumor volume in patients with sporadic AMLs but was associated with a high rate of treatment termination due to patient preference or prespecified AEs. Neoadjuvant EVE may be useful in potentiating surgical resection of large or anatomically complex AMLs. Clinical trial information: NCT02539459.
The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer.
Aggarwal, Rahul , Alumkal, Joshi J. , Higano, Celestia S. , Yu, Margaret K. , Boer, Carla de, Choque-Gonzales, Gonzalo, Szmulewitz, Russell Z , Bryce, Alan H. , Small, Eric J.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS5084-TPS5084

10.1200/jco.2015.33.15_suppl.tps5084 Get It